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HISTORY 
This thesis is concerned with the design and preparation 
of certain organic compounds which are expected to have medicinal 
properties. A discussion will be given whic:h has essentially a 
two-fold purpose. TI1e first is to discuss somewhat briefly the 
currently accepted method of ~rug design,and the second to show 
to what extent thfs method has been followed in the design of 
the compounds prepared. 
In the design of potential drugs there is in some measure 
a system which the designer should follow. This system, known 
as the method of variation, enables the designer to reduce to a 
minimun the degree of randomness or chance tn searching for new 
medicinals. The usefulness of this method has increased through 
the years as scientific knowledge f n general and the knowledge 
of medicinal chemistry and pharmacology in particular has increased. 
We must acknowledge, however, that untf 1 the fundamental chemica1 
phenomena proceeding in living things,and the mode of drug 
action are fully understood, this method wf 11 not attain to that 
perfection which is desired. 
TI1e method of variation consists first in the selection of 
a compound which is known through previous investigation to elicit 
a certain response. TI1is prototype as it wf 11 be referred to, may 
or may not: be a clinically useful drug~ or I~ may be a molecular 
group which is a portion of a molecule known to have medicinal 
properties. 
Once the prototype has been selected the designer shoull 
familiarize himself with the compound. He should seek to know: 
tt(l) the nature of the chief chemical classes to which the product 
2 
belongs. as determfned by the maf n stem nuclei or hydrocarbon 
skeleton from whfch ft derives its' name; (2) the nature and number 
of various functional groups that may be present, their positions, 
and the proximities of such groups with respect to one another; 
(3) the various possible degrees of rotation and extension of the 
structure tnto various spacial configurations; (4) the lf kelfhood 
of steric hindrance between various portions of the molecule 
in different configurations in space; (5) the likelihood of 
electronfc interactions between various portions of the molecule 
including such matters as inductive and mesomerf c effects. 
hyperconjugatfon, ionizabf lity, polarity, the presence of regions 
of relatively high or low electron density. the possf bf Uty of 
chelation, zwf tterion formation, etc. The designer should ~hen 
begin to consider the afore mentioned attributes in the 1 iGht of 
the substance's known pharmacological properties. A knowledge 
of the structures and pharmacologfc effects, of other substances 
. having essentially the same- or even remotely similar, sites or 
types of action as the prototype wi 11 also be fnvaluable."1 
After the designer has familiarized hfmse1f with the properties 
of tho prototype, he then proceeds to make variations on the 
prototype. The methods of approach and the variations to be 
made are actually peculiar to each situtation and no clear cut rules 
can be laid out which must be followed exactly by every designer 
of drugs. Rather it ts important at this point to discuss 
orientations of approach in drug design. Tilis approach may involve 
any one or more of three general main streams of thought, the 
method of fsosterfe replacement, the method of conjunction aad 
the method of disjunction. Again, there are actually no clear cut 
lines of demarcation between these three methods, but by such 
3 
classification df scussfon of drUg des~gn is facilitated. 
Langmuir2defined isosteric molecules as molecules having 
the same nunber and arrangement of electrons. Based upon similar 
considerations the concept was extended by Huckel and Grimn to 
certain chemical groups. It was found that chemical groups having 
the same number and arrangement of electrons show great similarities 
in physical and chemical properties. Examples of some of these 
isosteres are given below: 
(1) N2 and CO 
(2) N20 and co2 
(3) CH2=CO and CH2=N2 
(4) organic compounds which possess one 
or the other of the isosterfc pairs below 
and which are otherwise identical, · 
4 
exhibit strikingly simf 1ar physical properties: 
a) -N= and -CH= 
b) -0-, -NH- and -CH2-
c) F-. HO-, NH2- and Cff3-
d) Ne, IE, H20 and Nff3 
Tilus in designing drugs the method of f sosterfc replacement 
Involves substituting tsosteres into the prototype. In doing this 
the properties of the molecule are modified so as to enhance or 
diminish the desfrab1e medicinal properties of the molecule, but 
not radically. frequently. however, in practfce, while employing 
the general approach of isosteric replacement, workers substitute 
groups which do not fulfill the definition of isostere as set 
forth by Huck.el and Grimn. F.or example, they may substitute a 
cyctohexyl group for a phenyl group,or even a naphthyt group for 
a methyl group. Obviously, in such cases the term f sostere loses 
5 
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its meaning, but the approach is stf 11 good. The greater the 
deviation of the isosteres from true isosterism the greater the 
expected variation in medfciaal properties of the products. Wide 
variation eould lead to fnterestfng compounds having neW properties. 
In this thesf s compounds have been prepared fn which large 
groups of wide diversity of structure have been substituted into 
the parent nucleus. In some cases these large groups themselves 
have desirable medicinal properties. 
"The method of disjunction fn drug design might be considered 
as the formulation of analogues of a prototype. toward structurally 
simpler products which may be viewed as partial replicas of the 
prototype.'' 3 This method of variation is clearly cf4.monstr:-.:..ted 
by the investigations of Dodds, Cook• Robinson, and others in thef r 
work on estradfo1. This compound is known to elicit certain estrogenic 
responses. It consists of a lar.ge .an~· relatively planar nucleus, 
a phenolic hydroxyl group and the secondary alcohol g-oup. These 
investigators screened a large number of phenols, ketones, hydrocarbons, 
etc. and came up with diethylsti Uiestro 1 as the main grouping 
for estrogenf c activf ty. 
example of the method of df sjunction is very interesting and worthy 
of consfderatfon. Consfder the structures gfven on the next page. 
Be1rfng in mfnd that these investigators were seeking the simplfest 
structure whfch possessed optimum estrogenfc activities, they 
proceeded to <lisjoin or open the rings 8°and C, t') substitute 
s 
aromatic rtngs for saturated cyclic rings and decreased the size 
of the hydrocarbon portions of the molecule. AJJ of this f s 
evidenced fn structures II, Ill, and IV. At this point it was 
observed that the estrogenic activity progressively decreased in 
compounds II, Ill, and IV. Their next course of action was, 
however, not to reform rings 8 and C, but to prepare,,c,.,/3-df-
alkyt derivatives of stilbestradiot. By plotting activity versus 
structure they found that maximum activity was reached in df-
ethylstilbestrfol (VI). It Is fnterestfng to note that the 
distance of separation of the hydroxyl groups in diethylstilbestriot 
is the same as in estradiol. This distance, 14.S ~' is apparently 
the optimum distance for estrogenfc activity. 
0 
o)r 
14.5 A 
"Drug design through conjunction is defined as the systematic 
formulation of analogues of a prototype, in general, toward 
structurally more complex products, which may be viewed as structures 
embodying. in a general or specific way. certain or alt of the 
features of the prototype.114 An example of this method. given 
below, involves an approach which might be termed the principle 
of mfxed mof ettes. A mof ety is regarded as a molecular grouping 
which elicits a certain response. Frequently ft is desirable 
to design a compound which has the medfcina1 properties possessed by 
t..:> or more individual moieties. Such a compound would be prepared 
by uniting in a very specific way the moieties whose properties 
are desired. 
6 
•f'uture success f n the use of the principle of mixed moieties 
depends fundament~lly on how successfully pharmacologists 
and medicinal chemists wf 1.1 .be able to pin down. in a relatively 
certain fashion. various individual moieties that activate given 
molecular-level processes. Thus the primary problem at present 
is rather like t.he problem that faced organic: chemistry when 
it first became endowed with the concept of specifically charact-
erizable functional groups. As such groups became more firmly 
established as a basis for classifying the reactions of organic 
compounds, the possibilities of predicting the character of 
compounds embodying two or more such groups became more and 
more feasible. An analogous type of development in the field 
of medicinal chemistry involves formalization in a specific 
way of the much more complex individual pharmacophoric 
m&ieties, and this 'lr40u1d presumably lead to the possibility 
of predicting, with a fair degree o1 certainty, the effects 
of drugs embodying two or more mof etf es.116 
The example of this method involves the preparation of a 
c:omPound which has effective action ctn postganglionic 
parasympathetic neuroeffector cells and also is a ganglionic 
blocking agent. Host ganglionic blocking agents are bis-
quaternary salts, and it seems that fn the most effective 
ganglionic blocking agents the nitrogen atonis are separated 
by the same distance as f n hexamethoniun. Now, while compounds 
producing ganglionic blockade are effective in towering the 
blood pressure in hypertension. they also have their undesir~b1e 
side effects. for instance,, decreased intestinal tone leading 
to constipation.7 °Since these undesirable effects are the 
result of a lack of a significant degree of specificity for 
7 
sympathetfc ganglia in comparison wf th parasympathetfc ganglia, 
one way of increasing paresympathetfc tone wfthout~decreasfng 
ganglionic blocking actfvfty on the sympathetic side must be 
sought. Fortunately, the requirements for effective action 
on postganglfonfc parasympathetic neuroeffector cells are largely 
fndependent of the requirements for ganglf onfc blockade. For 
example, acetyt-~-methylcholine ts an effective postganglfonfc 
parasympathetic stfnailant f n doses whfch effect no sugnf ffcant 
a1teration fn ganglionic function, while hexamethonium has 
only a slight action at postganglf onfc parasympthetfc endings 
in doses that produce a high de9ree of ganglionic blockade. 
The mof ety requirements for pastgangtf onf c parasympathetic 
stimulant action (muscarinfc mofety) are sunmarfzed as 
shown below, referred for convenience to the structure of 
·acetyl cho l i ne •. 
g CH +~~)CH 
. CH/ 'o" 2---cH: tH 3 3 '"Z 3 
AcetylchoJine 
(CH3 >3-n± CH2-CHz-CH2-Cff2-CH2 -CH2!t1-(CH3 >3 
Hexamethonf um 
''The above genera1fzatf on of the muscarfnfc moiety when 
reviewed fn relation to the bisquaternary type of structure 
fn hexamethonium, suggests the fo11owfng design, embodying both 
the gang1f onfc active moiety and the muscarinfc moiety. 
Muscarfnf c Moiety 
(CH3}3-tf!c"2-CH2-0-g-CH2-cH2-f"Cctt3)3 
Ganglionic Active Hofety 
"Actual synthesf s and test of this product reveals it to 
be, unfortunately, both a muscarfnfc stimulant and a ginglianfc 
stimulant. A close hanolgue, 
8 
(C2Hs)3!N-CH2-CH2-0-g-CH2-CH2-N!(C2Hs)3 
however, is a produvt havfng desired type of mixed actf on. 
It is both a ganglionfc blocking agent and a weak muscarinfc 
stf mu1 ant. u8 
Since the compounds prepared fnthe present papesr :are al I 
dertvatives of (J-aminoethy1pf perazine this compound wit 1 be 
considered the prototype and a discussion of fts chemical and 
stereochemical propertfes wf 11 be given. It should be pointed 
out however, that frequently large groups have been attached 
to fi-amfnoethy1pfperazfne, and that these large groups mfght 
just as well be considered the prototype. Therefore, following 
the dfscussfon of ~-amfnoethylpfperazfne there wf11 be a 
somewhat briefer discussion on each of the compounds prepared. 
The followfng is the structure for ,6-aminoethylpfperazfne: 
N112-C"2-CH2-0 
It fs easily seen that thfs compound contafns both fnsfde and 
outside the ring, the -M-C~-CH2-tr.:. groupfng. This grouping 
and its isosterfc analogue (-O-CH2-ctt2-N~ ) are frequently fn 
many different types of pharmacEutical agents, for example, 
local anesthetics such as procaine. 
adrenergfc blocking agents such as pfperoxan, 
parasympathomimctic agents such as acetylcholfne. 
9 
antispasmodf cs such as adiphenine, 
and antf hfstaminic.agents such as diphenhydramine, 
and trf pe1ennamine. 
Most of the more active antihistaminf c agents contain this groupf ng.9 
Chtorpheni.namine fs an interesting example of a powerful antfhfstcmfne 
drug in which the fsostfc moiety ts -c-ctt2-ctt2-t~ • T~is evidence 
alone is very strfkfng and therefore strongly suggests that 
the ~ -aminoethylpiperazfne grouping would be expected to have 
favorable properties in its compounds. 
Pf perazfne itself f s relatively non-toxic and ts now used 
fn the form:·of its cftrate astthe agent of choice fn the 
treatment of pfnworm fnfestation.118 
The nature of drug action fs:by no means fully understood. 
There fs sane evidence, however, that drugs combine with 
reception by coutanbfc forces at some stage during their actions 
and most receptors are proteins. The polypeptide nature of 
proteins fs welt understood, the bonding being explained in terms 
of the linking together of amino acids through thefr a(.- emf no 
and carboxpt groups. The spacing between these polypeptide 
bonds f s regular and this spacing .f s known as t)te fdentfty 
distance. Thfs distance is equat to 3.61 R. A diagram iltustratfng 
this is given below: 
10 
XR r,, t. v 
' t;" l ~"" N " ' 
ti I R ff ~ L I 
3.61 i 
In compounds of known pharmacho1ogfca1 actfvity the 
distance separating the functional groups frequently is found 
to be equal to the fdentfty distance or some whole number 
11111tip1e thereof. In a given series of compounds tn which all 
features are the same except the distances separating the 
functional groups,optimum activity ts frequently observed fn 
the member of the series fn which this fdentfty dfstance or some 
whole number multiple thereof fs observed. Thfs indicates that 
if there is an attraction of certain groups ~n a drug for tho 
nitrogen or oxygen atoms or both in a protein, the drug becanes 
more firmly attached ff the functional groups fn the dr-ug are 
separated by some whole nunber multfplo of 3.61 K.1 l 
"Many parasypathomirnetic (acetyl choline like) end 
parasympatholytfc (chotinergic blocking) agents have a ,eparatf on 
of 7.2 R between the ester aarboxyl group and the nitrogen .. This 
distance is doubled between quaternary nftrogens of curaretfke 
drugs; 14.S R . The preferred ~separation of hydrogen bondfng 
groups fn estrogenfc compounds is t4.5 R. 12 
Novet calculations of interatanfc dfstances info-aminoethyl-
piperazfne show that in the ethy1endfamfne moiety, planarity 
of' H,e;fc,u and tack of bond strain make tho distance between 
nitrogens 3.75 R. Atso, catcu1atfons show that the distance 
0 
between nitrogens fn the pfperazfne moiety is 2.87 A and the 
0 dist~nce between terminal nitrogens is 6.60 A. The calculations 
fol 1 ow: 
11 
According to Aroney and le Fevre, 13,l4 piperfdine and 
ii ,, 
cyclohexane exist predominately in the chair conformation. An 
ary1 group attached to the nitrogen atom fn pfperidine lf es fn 
an equatorial posttion. This apparently is due to the size 
of the group.rather than to any electronic interactions with 
the ring. Stated dffferentty, the aryl group Hes in the 
equational position because this position is sterically favored 
over the w.xfal position. These authors also found that piperazine 
exists as a mixture of the 11chair11 and 1'boat" conformations. 
The positions of the nitrogen atoms in the rings in their two 
conformations are Indicated by the following diagrams: 
11Chair11 "Boat" 
Unsubstituted piperazine exists as a mixture of four structures, 
three of whf ch have the cha fr conformation and one the boat, 
as indicated below: 
H 
H 
A: B ·c D 
With regard to the relative abundance of each species~ there 
is more 8 than A or c, end D fs present in about double the 
amount of B. When phenyl groups are attached to the nitrogen 
atoms to form 1,4-dfphenyl pfperazfne the compound consists of 
a mixture of the fol lowing two' conformations with F predominating. 
12 
Ar 
E F 
In order to determine the stereochemical structure of 
~ -aminoethylpfperazfne, certain conclusions,based on the evidence 
given above, must be made at this point. Ff rst, ft seems 
reasrinab1e that the compound must exf st as a mixture of the 
11chair11 and "boat" conformatf ons wfth the latter predomfnating, 
sf nee thf s f s the case wf th unsubstituted and disubstituted 
piperazfnes. Secondly, from steric considerations, ~he 
amfnoethyl group most probably assumes an equatorial posftfon, 
even though &<:cording to Aroney and LeFevre the 1,4-dfmethylpfper-
azfne has a small amount of the axial ~chafr"form fn the mixture. 
The axial methyl dfrfvative is not nearly as sterically hindered 
as would be the case with the ethylenedfamine wf th a large group 
attached in the ,8-posftf on. 
In conclusion, the p -amfnoethylpiperazfne grouping in 
the compounds prepared in this thesis is to be regarded 
as consfsting of a mixture of the chair and boat forms.with the 
f.5-aminoethyl group attached in equatorial positions as indicated 
below. 
It remains to determf ne the distances separating the nitrogen 
atoms, ie., the shortest df stances from 1 to 2, from 2, tti'3, •nd 
from 1 to ]. 
13 
,, 
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A diagram of ~· -amf noethy1pfperazfne fs given belows 
The C-N and C-C bond distances are J.47 A and 1.54 X, respectfvely. 6 15A 
The NCC and CNC bond angles in the ring are tetrahedral! 109.5C? The 
CNC bond angles outside the ring are 10s<? 
Since the pfperazine ring f s symnetrical. a straight line 
COMecting N and N• must pass through the center of plane ABCD. 
Therefore• the distance NO, whcrre 0 f s the center of the plane. 
must equal half the distance separating the nitrogen atoms f n the 
ring. In determining NO, NE and EO must be known. NE is given by 
the fol lowing equation: 
cos L NAE = (l;0>2+ (A£>?:. (NE)2 
2(NA)(AE) 
0 . 2 2 2 
cos 109.5 · = (1.47) + (0.77) - (NE) 
2{ i .. 47)(0.77) 
(NE)2: (1.47)2+ {0.77)2~ eos 70.s°(2)( 1.47)(0.77} 
. NE = l.87 l 
*Aroney and Lef'evre assume angle CNC to be tetrahedral in their 
'WOrk on pf perazf ne. 
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The length of EO is determined as fo1Jows1 Since lines AC and BD 
are parallel, line AB= EF, both being perpendicular to the same 
lines. A lfne drawn perpendicular from AB to N bisects AND. 
0 Since ANB = 109.5, ANJ = si+.1sa. 
sin 54.8° = AJ 
NA 
= AJ 
CT7 
AJ = (.817)(1.47) = 1.20 
Since AJ = EO• EO is also 1.20 ft. 
Tilerefore, (No) 2 = (NE)2- (Eo)2 
.NO = J (1.87)2 - (1.20)2 
NO = 1.437 ft 
The distance of separation of the nitrogen atoms in piperazine is,, 
therefore, 2(1.437) = 2.87 ft 
Tile df stance between the nitrogen atoms in the ethylenediiJrnine. 
portion of the molecule. will now be determined. 
Since the carbon and nitrogen atoms are all considered to lfe 
In the same plane fn the ethylenedf amfne portion, and thf s portion 
is also symnetrfcaJ, the distance NO' is equal to half the NN•• 
distance. Therefore, 
2 2 2 
cosLHIO• = (NI) + (10 1 ) - (NO•) 
2(NI)(IO•) 
cos 109.5°= (J.47)2 + (0.7712 - (N0)2 
2( 1.47)(0.77) 
N0 1=1.87 R 
NN 11= 3.74 ~ 
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It remains now to determine angle H11 NN'. This angle wf11 be 
the sum of angles N• 1NI, INJ, and JNN•. Angle INJ is determined 
as fo11owsi Angles IND and INA are 108°. f'or the sake of more 
convenient calculations. rather than determining angle INJ directly, 
its• supplement wf 11 be determined which is angle HNJ, where angles 
HNB and HNA are the supplements of angles INB and INA, and equal to 
7t' (180-tOa°). Angle INJ wi 11 then simply be the supplement of 
angle HNJ. 
By dropping lines from ff to points K and L on the plane NAB 
where line HL is perpendicular to the plane and HK is perpendicular 
to line NA. angle HliJ can be determined as follows: In the right 
triangle HNK, Jfne HH is equal to the nitrogen-carbon bond distance, 
since in this case line NH is formed by rotating line NI. Therefore: 
cos LHNA::: NK 
NH 
cos 72 = NK 
1.47 
NK = (l.47)(.309) 
0 
NK = .454 A 
Since angle AHB is bisected by NJ. angle ANJ is equal to -!Ct09.s°), 
or t;4.7tf', and since HK is perpendicular to NA, KL is also perpen-
dicular to NA. Therefore: 
cos LANJ = NK 
NL 
cos 54.75 = .454 
NL 
NL= .454 
.577 
NL = .786 ft 
16 
NL is also the base of triangle HNL, therefore, 
cos L.HNJ = NL = .786 : .535 
NH t.47 
LHNJ = 57.3° 
. . . . . 0 0 
Angle INJ is therefore (180-S].J ) = 122.7 
In triangle NJO, line JO fs equal to i(t.54) or .77 X, and 1fne 
HO is t.437 1. Since triangle JNA is a right triangle,and angle ANJ 
is S4.1f: and line NA is t.47 ft, it follows that: 
Therefore: 
cos LANJ =NJ 
HA 
cos 54.75 = NJ 
1.47 
0 
NJ = ( .577)( t .47) = .848 A 
2 2 2 
cos L JNO = (NJ) + (NOl - (JO) 
2(NJ) NO) 
2 2 2 
= {.848) + f.1·437! - (.77) 
2( .8 )(1. 37) 
= .899 
. L JNH 1 =LJNO = 26° 
Since in triangle INO•, the lines N0 1 , NI and IO• are 1.87, 
1.47 and .77 R respectively, it follows that: 
. 2 2 
cos L INO• = (NO•) ~ (NI12- (IO•) 
2(N0 1 ) NI) 
2 2 2 
= 0.87) + (J.47) - (,V) 
2(1.87)( I .47) . 
= .923 
L INH''=LIN0 1 = 22.7° 
0 Therefore., angle N• •NN 1 :is 171.4 which ts the sun of angles N• •NI, 
lNJ, and JRN•. 
17 
1be distance separating the terminal nitrogen atoms in ~ -amino-
ethylpiperazine, (N• •N•), is determined below: 
cos L N11N1 :: (N• •N)2+ (NN•)2-iN' 1N1 ) 2 
2(N 11N)(NN 1 
cos 171.4° = ().74) 2+ (2.87)2-{N 11 N1 ) 2 
2(3.74)(2.87) 
' 0 
N• 1N1 = 6.60 A 
'Dlis distance is a little short of double the identity distance 
{7.2 >l). 
In proteins there is hydrogen bonding between adjacent chains 
17 
of polypeptides as indicated below: 
tt }l ~ ~ H~ c ff 'c 
'g/ '~/ ..... ,c..,. ...... c / ....... r( 
HR 0 H 
I ~ i ' I I J;I HI 'if ~ ,N......_ ......._ ' N 
c ...... ~ / 'g ............. ,; ' tf R H 
It shou1d be pointed out that ff medicinals combine with protein 
receptors in part through hydrogen bonding in a similar manner, 
then the distance separating the hydrogen atoms attached to the 
functional groups is also of some concern. In open chain medicinals 
and polypeptides the hydrogen atoms are, as indicated above, separated 
by the same distance as the functional groups. In aminoethy1-
piperazfne, however, the hydrogen atoms attached to N• and N•• 
are not exactly perpendfcuJar to line N••N•, but rather are in-
clined at angles approximating 100°, as shm-"~ below: 
! I 
The distance separating the hydrogen atoms is. therefore. somewhat 
0 
18 
greater than 6.60 A. The hydrogen atom at N1 is here considered as axial. 
I _ 
TI1ere are many compounds having medfcf nal properties 
which contain the,8 -aminoethypiperazfne moiety or some grouping 
very close to it. Several of these compounds will now be 
ment tonerl. 
(1) The following series of compounds are known to be 
effective as vasodi1ators and adrenergfc blocking agents. 18 
(A) @,~) -N-CH2-CH2-Q-R R:: -CH3 . 
C2H5. . Q 
= -t:-CHl 
= -C6HS 
= -Csff4N 
:: -H 
R :: '."CH) I R =·-C6H5 
= -Cfii-C6HS 
0 
= -C-CH3 
In a11 of these compounds the maximum activity was 
obtained when w=2 as represented in the formula below 
R-:-{CH2ln-~-R 
= -CH3 
:: -C6H5 
?{2) The compound 1,4-df(2-pyrazy1 )pi perazf ne was prepared 
as a potential anticonvulsant and is a very active analgesic.1 9 
(3) Prochlorperazine is an excel lent antiemetic in man 
, 20 
and has been of value in mild neurotic disturbances. 
19 
(4) 
sedat1on of psychoneurotic individuals and for treatment of 
tension. anxiety, insomnia, and senile excitation.21 It might be 
well to point out that, as mentioned previously, -0- and -NH-
. ,_ ' 
are isosteric groups and, compounds containing either of them 
and which are otherwise fdentic:a1 are expected to possess. 
-sf mi tar properties. 
Cl~-fH· ~-CH2-Cil:!-O -CH2-Clf2-0H 
© 
(5) The compound, l-[N, N-dimethyl-n-(6-cyano-6,6-dipheny1-
hexy~ium)ethane-2-(N-m'ethy1morpho1ino) dichloride, has been 
used with good results in the treatment of hypertension. 11The 
spacial receptor protecting effect of the large groups may be 
so overpow9ring that the strongly polar properties of the qua-
ternary nitrogen atom can be abandoned in favor of tertiary 
amino groups. This is seen in many typical antispasnodfcs 
whcf h cause only a barely detectable parasympathetic ganglionic -
blockade." 22 
®· 
@--(CH2)5-~lffi-CH2t~ •2C1--.. CH3 ·~ ( I -..../ 
- (6) The compound• 1-lfl-{dimethylamino)ethyfl -4-phenylptperazine, 
is a very eff~ctfve antihfstamfne.23 
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CH3~~2-C11z-~-~ 
(7) Lfnadryl is an effective antfbistamfne.24 
~(2J~~O-CH2-Cffi-~ 
( I 
\. _, 
Therefore, wt th regard to the prototype, " -amf noethyl -
piperazfne, it might be stated by way of stmmary thats (I) the 
compound contains the ..X-CH2-CH2-N grouping which is present in 
a wide variety of medfcina1s; local anesthetics, adrenergic 
blocking agents, parasympathomimetic agents, antf spas:modics and 
nearly a11 of the- antibistanines; (2) the distance of the terminal 
nitrogen atoms is close to twice the identity dfstanc.eJ (3) 'there 
are a number of compounds i1avlng a wide variety of medicinal 
properties whiti::h contain a grouping close to,if not identical to, 
-aminoethylpiperazine; (4) pfperazine is a relatively non-toxic 
substance. An additional fact of significance which has not 
been mentioned previously is that fn many antispasmodics-t,:~ps 
!'s~ as pyrrolidine1 pipertdine and ptperazine behave as anchoring 
groups.25 
Rarely is a qrug found which has only one action on the 
organism as a wb:>le. For instance# antihistamines exhibit fn 
some degree the properties of the 1oca1 anesthetics, sympatholytfc 
agents, antispasmodics, sympathomimetfc agents, analgesics and 
anticholinergics.26 This indicates that the mode of drug action 
for alt these types of compounds is probably similar. Therefore, 
when a compound is designated as an analgesic, antib'istamine, 
anticholinergic:, etc., this probably mea:ts that the groups attached 
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to the main stem nuclei enhance f ts 1 properties as an analgesic, 
antihistamine, anticholinergic, etc. 
The derivatives of /3 -aminoethylpiperazine can be expected• 
therefore, to have medicinal properties, and the mode of drug 
action can be expected to be the same as 111 the analgesics, 
antihistanines, anticho1inergics, etc. 
A brief discussion will now be given un each compound prepared 
tn. this thesis. In some cases large groups which themselves 
have certain specifically characterizable pbannaculogica1 properties 
have been added to the 13-aminoethylpiperazine nucleus. In those 
instances the prepared compounds should be viewed as having 
properties characteristic of all their moieties. In most cases 
the propertfes of these groups added to the parent compound are 
hanmnious with the properties expected of P. -aminoethylpiperazine. 
In other cases where the properties of the groups added to the 
parent molecule are less specific:a11y characterizable,, the 
products should be regarded as having the same properties expected 
of 13-arninoethylpiperazfne with relatively mild varfatfons. The 
compounds prepared in this study are given below and are assigned 
Arabic: minerals. The compounds from the literature are indicated 
by capf ta1 letters. 
~ff ~~-Clfi-~-cH3 (1) 
1-[P-(Cyclohexylmethylamfno)ethyt]-4-methylpiperazine 
This compound can be regarded as the product resulting from 
the replacement of compound (l)-(A) on page 1<J. and, therefore.is 
expected to have properties as a vasodilator and an adrenergic 
blocking agent. 
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(2) Due to the close structural simi tari ties of camphot~ and 
norcamphor, the following two compounds are discussed together 
and are expected to have nearly the same properties. 
1- [,e-[J,7,7-trimethyl-2-(bfcycJo ~.2.i] heptyl)amh~ 
· ethy!J-4-methylpiperazf ne 
Cf)-NH-Cllz-CHz-0 
1- l_i3-[2-(Bfcycfo[2.2. I] heptyt)amfno]ethy!J piperazf ne 
Camphor has many interesting pharmacological properties. It 
27 . 
f s an anaJeptic. it is used as a circulatory and respiratory 
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stfmu1ant~8and locally as a mild antiseptic, analgesic and antipyretic~9 
Compounds containing the 1-phenyl-2-aminoethane moiety are 
regarded as sympathomfmetic amines and are classified broadly as 
ana1eptics~0 In view of the fact that this structure resembles 
~-CH2-cH2-NH2 
amfnoethylpiperazine in certain features and ~hat compounds of this 
structure and camphor are both analeptfcs, the camphor derivative 
of P., -aminoethylpfperazine is expected to have analeptic properties. 
One of the undesirabJe properties of camphor is its' water fn-
solubilfty and, consequently, attempts have been made to prepare water 
so hi ble derfvatlves11 The camphor derivative of f.3-aminoethylpiper~ine 
has Increased water solubility over camphor. 
4) 
5) 
1-[P-(MethyJ-1,2,3,4-tetrahtdro-o<.-naphthylamfno 
ethyU-4-methylpiperazine 
@j-CHz-CHz-0 
1...[p-( J,2,3,4-Tetrahydro- o(-naphthy1amf no)ethyf] 
pf perazine 
The followfng compound has been prepared as an antfhistamtne. 
8) 
1,4-Bts(2-methyl-1,4-benzodfoxane)pfperazfne 
It ts a property of the benzodioxanc antf hf stamine drugs to cause 
adrenergtc blockade. This compound also has considerable central 
nervous ·system depressing propertfes.32It can easily be seen that 
in this compound the oxygen and nitrogen atoms are separated by t1llO 
carbon atoms as in most antfnf stamfnes and that thfs compound con-
, tains the pfperazine ring. Also, the groups -CH2- and -0-, ft wf 11 
be recalled, are isosteres. The tetrahydronaphthyl derivatives of 
,B-aminoetbylpiperazine and the benzodioxane derivative of pfperazine 
all contain the flat planar benzene ring attached to a non-flat, 
non-planar rfng. This indf cates that the two compounds, (4} and 
(S), will have antfhistamfnic properties. 
Hethy1atfon of the amf no groups of a compound tends to decrease 
toxicity~ but also tends to decrease actlvf ty.33 
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1-[p -(Dicyclopropy1methy1amino)ethyj]piperazine 
7) [> -f H-NH-CH2°CH2-QH 
© 
1-[.P'-(o(-Cyc1opropylbenzy1amino)ethy[)piperazine 
8) [>-cH-NH-CH2-C"2-0H 
CH3 · 
1- (p-(o'-.-Cyclopropy1ethyt amino)ethyl]pf perazi ne 
Few compounds related to the above structures have been prepared 
in which cyclopropane is used in place of a straight chain hydro-
carbon. Therefore, although these compounds are expected to have 
properties as vasodilators and adrenergfc blocking agents similar 
to those of the derivatives of ,8-amnfoethylpiperazine mentioned on 
I 
page 19. a prediction of any property modifications is not possible. 
The following two compounds are similar fn some features to the above 
compounds, but the analogy is not too good. 
C) ~~j'\~-O-CH2-cH2-N-(C2H5l2 
/3 -Di ethy 1 ami noethy l-1-benzoy 1eye1opropa:1ecarboxt1 ate 
This compound is an antispasmodic and contains the -O-CH2-ctt2-N 
34~-groupfng characteristic of the antihistamines. It also contains 
a phenyl and a cyclopropyl group as in compound (7). 
D) @-D-N112 
2-Phenylcyelopropylamine 
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Compound (D) has been used as a mood e1evatf ng drug.35 
It can be seen that this compound c1ose1y resembles the~ -
cyclopropy1benzy1amino moiety In compound (7). 
An additional fact of interest ts that, cyc1opropane is 
well known as an anesthetic of low toxicity and high therapeutic 
f ndex.36 
9) 
10) 
f H3 
. Qt:~2-CH2Qi-CH3 
1- 1]9-(Acety1cyc1ohexy1amino)ethy(]-4-acety1 
piperazine 
©. ~H3 Q =O R C"'2- -Ctf2-CH2- -C-CH3 
1-[,B-(Acetylbenzylandno ethyt]-4-acetylpiperazine 
These compounds are also expected to possess priperties as 
vasodilators and adrenergic blocking agents. but again, it is difficult 
to assess the property modifications resulting from acetyJation 
of the nitrogen atoms. Some compounds containing the grouping, 
RCONR2, have anticonvu1sant properties.37 
11) (CH3)2-C=CH-CH2-CH2-~~~H-CH2-~ff-C"2-CH2-~H 
1- [ tl-(3,7-Dimethy1-2,6-octadieny1amf no)ethy1]piperazf ne 
Citrat, (CH3)2C=CHCH2CH2C(CH3)=CHCHO, is known to possess 
antf-inflarrmatory. antia11ergic, antispasmodic and analgesic 
propertfes.3B,39 
uAccording to the modern mediator theory, pain arises as a result 
of the chemical mediators histamine and acetylcholine. Solutions 
of cf tra1 possess antihistamine and antichoHnergic activity. 1he 
double bond in the 6-7 position does not play an important role in 
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antihistaminic activity. 1lle aldehyde group is not essentf ai for 
antihistaminic activity. Thus the atcohot, geranio1, is just as 
effective as the aldehyde., citrat. The antihistaminfc activity of 
citrat and its• derivatives is not produced by a certafn.molecular 
group, but is a property of the molecule as a whole, wherein con-
siderable changes in structure may be made without greatly affecting 
the activity.40Citra1 also reduces blood pressure in concentrations · 
of hloo,ooo.'+1 
The same properties are thus possessed by citral as those 
expected of /> -amfnoethyJpiperazine and the union of these two moieties 
should give a compound having antfhfstamfnic, anttchotinergic, and 
vasodilator properties. 
Although this thesfs fs not concerned wf th drugs of possible 
use in the treatment of cancer, ft is interesting that citrat has 
42 inhibitory action on tumors (sarcomata) in mice, and it liquefies 
spontaneous tumors (carcinoma of the mammary gland) in mice. 
Citral is non-toxic to normal cells in doses which cause regression 
in malignant tumo~s.43 
12) 
H3C,pH3 ~H (\ OCH=Cll-tH~NH..CHz-Cffi-~ CH3 
t-fp-[}-(2,6,6-Trfmethy1-2-cyc1ohexyl)-1-methy1-
2-propenylamino]ethyij.pfperazfne 
o(-Ionone is a substance of very low toxicity. When injected 
·· into an animal, 2 g./kg. body weight, it is e1eminated through the 
44 lungs without accident. In clinical tests, tf-ionone, also of tow 
toxicity, had neurotropic, antisympathfcomimetic. and antispasmodic 
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H C CH 
3 '' 3 CH) ~~CH-C=O 
f1-lonone 
E) 
activity.45,B-Ionone also has high antfcholfnergic activity.461n 
very dilute solutions, 6 x 10-6 to 6 x 10-7, it reduces the activity 
of hfstamfne by SO - 70% in sections of guinea pig fntestine.47 
Little work has been done on the pharmacology of o<.-ionone 
however, but, due to the close structural stmt1arittes, the pro-
perties of o<- tonone are at least somewhat predictable from the 
properties of .61-fonone. If this 1 s true, then the properties of 
o( -lonone are harmonf us wf th those expected of P' -ami noethyl -
piperazine. 
13) 
~H3 
ONH-CH2-CH2-0 
H3c' CH3 
1- LP-(2-Isopropy1-5-methy1cyc1ohexy1amino) 
ethyl] pi perazi ne 
In one experiment, menthol depressed the isolated heart 
of both the frogc&iad rabbit by dilating the coronary vessels.48 
In another experiment menthol caused a fall fn blood pressure 
in cats and rabbits, and it blocked the vasoconstrictive action 
of nicotine when adninistered in the ratio of 1 part menthol to 
2 parts nicottne.491n still another experiment. menthol produced 
vasodtlation in the anesthetized dog.SOlhus compound (13) s~utd 
have strong vasodilator properties. 
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14) ctfa- pi- fH2 0 I CH3tf . CH-NH- Cffi-CH2- ~ CH2-CH-tt12 
1-[,8-( 3-Tropyl ami no)ethy1]pi perazi ne 
1be following compounds have been prepared and were found to 
have ganglionic blocking properties similar to hexamethonium.51 
These compounds also reduce the blood pressurt.::.52 
F) 
Compound (14) is not a quaternary salt, but ft,a114?,is expected 
to have vasodf lator and ganglionic blocking activity. It wf 11 prob-
ably be less active than compounds (F). 
1S} 
· t- [P-(2-Hydroxy-1,2-dfphenylethytamfno)ethyl]· 
· piperazine 
The foJtowing two compounds which are structurally related 
to compound (1S) 1 and are used as antispasmodics. 
H~ + --CH2-CH2- . .CH3S04 
~- HJ 
I I 
G) 
,_,' ricyc1amot 53 
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H) 
HexocycliumS4 
Barger and DaJeS>reported that certain compounds containing 
the moiety shown below act as vasopressors, and are termed sympatho-
mfmetic al'lfnes. They cause a rise in blood pressure coupled with 
vasoconstriction. 
I) 
Compound (1S) is, 
~l:H-Cll.I( 
therefore, expected to have properties as 
an antispasmocHc, and might be a vasodilator or a vasoconstrfctor. 
16) 
1- [p-(,B -Pyridy1methy1amfno)ethy1]ptperazfne 
The following compound has been found to be an effective vaso-
df lator, and f s useful in overcoming cold-induced vascular spasm.56 
J) @CHzOH I , 
p -Pyrf dy1methano1 
This compound can be regarded as being isosteric with the 
,B-pyridylmethylamino grouping in compound (16). Since the two 
moieties fn (16) have properties as vasodltators, it is expected 
that thf s compound wt 11 be a vasodl 1 ator. 
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The fol 1owfng preparations involve the condensation of a 
primary amine. 13·aminoethylpiperazine. with aldehydes and ketones 
to form Schiff bases.53The equation for this reaction is given 
below: 
The Schiff base is then reduced using sodium borohydr.ide (NaBH4) 
to form the secondary amine as indicated below: 
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EXPERIMENTAL 
1-[p-(Cyctohexytamino)ethyi] pf perazine 
ollll-~-~-o 
To 64.S g. (0.5 mole) of /3-amfnoethy1piperazine dissolved 
ha 100 mt. of absolute methanol was added SO g. (0.5 mole) of 
cyctohexanone with shaking. The reaction took place rapidly. The 
resulting mixture was allowed to stand for three days. To the mixture 
was added 20 g. of NaBH4 dissolved fn absolute methanol. The methanol 
was evaporated and to the resulting viscous liquid was added 10 g. 
of NaOH df ssolved in 50 ml. of water. The mf xture was extracted 
with two ISO ml. portions of ether. The ether portions were combined 
and the ether evaporated. The resulting 1tqufd was distilled. 
Yfeldt 35.4 g. (33.5%), b.p. 148-ISD°@ .6am. 
Calculated for c12tt25N3t titrable N, 19.90%. Found 19.62%. 
1-[S-(AcetylcycJohexylamfno)ethyi]-4-acetytpfperazfne 
~~~2-~-~-g-ci; 
To JS.4 g. (0.17 mole) of 1-[,8-(cyclohexylanfno)ethyj.J-
pfperazfne, from above, di ssl>tved f n 75 ml. of anhydrous pyridine 
was added 32 ml. (0.34 mole) of acetic anhydride wfth shaking and 
cooling. The volatile material was distilled off under a vacuum 
using a water evaporator. The resulting viscous liquid was distilled. 
Yields 20.1 g. (40.0%)~ b.p.228-232°@ .2nm. 
Calculated for c16tt29N3o2: tltrable H, 4.74%. Found 5.04%. 
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1- -(Benzytamino)ethyl piperazine 
To 64.S g. (O.S mole) of f3 -aminoethylpfperazine dissolved in 
100 ml. of methanol was added 53.0 g. (0.5 mole) of benzaldehyde 
with shaking. The resulting mixture was allowed to stand for three 
days. To the mixture was added 20 g. of HaBH4 dissolved in 50 ml. 
of methanol. The methanol was evaporated using an evaporator. To 
the resulting viscous liquid was added 10 g. of NaOH dissolved in 
a minimun amount of water. This basic solution was extracted with 
three 100 ml. portions of ether. The ether extracts were combined 
and the ether evaporated. The resulting viscous liquid was distilled. 
Yield: 43.2 g. (39.4%), b~p. 14S-1S0°@ .Snm. 
1- (Acety1benzy1amino)ethyl -4-acetylpf perazine 
~H3 
;-:::\_ ~=o 0 R ~CHi-N-Cffa-CH2- -C-CH3 
To 43.2 g. (0.2 mole) of 1-[,s-(benzy1amino)ethy1]piperazfne, 
from above, dissolved in 75 ml. of pyridine was added 37.S ml. 
(0.4) of acetic anhydride with shaking and cooling. The volatile 
material was distilled off under a vacuun using a water aspirator. 
The resulting viscous liquid was distilled. 
Yield: 19.9 g. (J2.8%), b.p. 225-230°@ .2nm. 
Calculated for c1,tt25N302: titrable N, 4.62%. Found 5.07%. 
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t-~ .[1, 7, 7-Trfmethyt-2-Cbfcyclo(g.2. j]heptyl )amfn~ethy]-pfperazfne 
To a solution of 64.S g. CO.SO mole) of P -amfnoethylpfperazfne 
dissolved in 100 ml. of absolute methanol was added 76 g. CO.SO mole) 
of camphor dissolved fn 100 ml. of absolute methanol. Fifty drops 
of phosphorus oxychlorfde was added and the resulting mixture was 
refluxed for 48 hours. 
The mixture was allowed to cool to room temperature end 20 g. 
of NaBH4 dissolved fn 200 mt. of absolute methanol was added fn 
small portions. After hydrogen evolution had ceased the mixture 
was evaporated to dryness in an evaporator. The resulting viscous 
gum was cooled and 300 ml. of 61! HCJ was added wfth cooling. A 
solid precipitate formed. The combined so1fd mass and solutf on 
was extracted four times wfth 1SO ml. portions of ether. The ether 
portions were discarded. The acidic layer was cooled and was made 
basfc wfth excess solfd NaOH. A yellow of I rose to the surface. 
The cOfDbfned oil and sotutf on was extracted wfth three 150 m1. 
portions of ether. The.ether was evaporated and the resulting oil 
was combfned with another portion of the same oit obtained from 
a precedure identical to the one above. The combined portions of 
oft were dfstf 11ed. 
Yfeld: 52.0 g. (18.3%}, b.p. 143-148°@ .]mm. 
Calculated for c16tt32N3: tftrab1e N, 151 85%. Found 1S.64%. 
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1- ~-[1,7.7-Trimethyl-2-(bicycto[2.2. Uheptyt)amtnii]ethy] -4-
methylpiperazine 
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In a three-neck flask was placed 66.S g.(0.2S mole) of 1- [fi-Ct, 
7,7-trfmethy1-2-(bicyc10[2.2.j] heptyl)amirxi} ethy~ piperaztne dissolved 
in 200 mt. of absolute methanol. A solution of 35.5 g. of methyl iodide 
in 150 mt. of absolute methanol was prepared. Half of this solution 
was placed in the refrigerator and the remaining half was placed in 
a separatory funnel attached to the three-neck flask. A reflux 
condenser was attached to the flask and a power stirrer was included. 
The methyl iodide was introduced at a slow rate fnto the solution 
being stirred. When the first portion of methyl iodide had been 
added the remainder from the refrigerator was placed in the separatory 
funnel and added slowly. The time required to introduce all of the 
methyl fodtde was about six hours. The reaction mixture was allowed 
to stand overnight. The methanol was evaporated and the resulting 
viscous gun was dissolved in 200 ml. of 6!! HCl. lbe acid solution was 
extracted with several portions of ether. The acid layer was made 
basic wf th excess solid NaOff. An oil rose to the surface. The 
aixture was extracted with severa1 portions of ether1 th& ether 
layers combined and evaporated and the residue was distilled. 
Yieldi 9.0 g. (12.9%). b.p. 214-218° @ )Onm. 
Calculated for Ctt"llN): titrable N• 15.04%. Found 14.97%.. 
1-~-Ei-(Bfcyclo 2.2.1 hepty1}amfn2) ethyiJ piperazfne 
To 27.6 g. (0.25 mole) of norcamphor dissolved in app.-ox-
fmately 75 ml. of absolute methanol was added 25.8 g. (0.2 mole) 
of # -aminoethylpiperazine. The mixture was allowed to stand 
for a few hours and then 6 g. of NaBH4 was added. After 
the evolution of hydrogen ceased the methanol was evaporated. 
To the residue was added 6!! HC1 until the solution was acidic. 
The acid solution was extracted with ether and was then made 
basic with excess solid NaOH. This basic solution was extracted 
with ether. The ether extracts were combined and the ether evaporated. 
The resulting residue was distilled. 
Yield: 10.9s g. {24.7%), 
Calculated for c13a25N3i titrab1e N- 18.81%. Found 18.31%. 
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1-[£-(11 21 3,4-Tetrahydro-o(-naphthylamino)ethyl]pfperazine 
cSCTtHi-tHi-o 
To a solution of 12.9 g. (0.10 mole) of fJ -aminoethylpfperazine 
dissolved in 100 ml. of absolute methanol cooled to to0 c was added 
14.6 g .. (O.JO mole) of 2.31 4-trihydronaphthone in small portions. 
The resuldng mixture was allowed to reflux for 24 hours after 15 
drops of phosphorus oxychtoride had been added. 
Following the refluxing the mixture was cooled in fee and 3 g. 
of RaBH4 dissolved in too mt. of absolute methanol was added. After 
the evottion of hydrogen ceased the methanol was evaporated in an 
evaporator. To this mixture was added 100 ml. of 6!! HCJ. and all 
the material went into solution. The acfd salutJon~waseextracted 
with four too mt. portions of ether. The acid layer was made basic: 
. with excess solid NaOH, and air-:oil rose to the surface. The solutfon 
was extracted with three 100 mt. portions of ether. The ether layers 
were combined and evaporated, and the residue was dfstf tJed. 
Yfeld: 31.0 g. (12.0%}. b.p. 180-189° @ Jmn. 
Calculated for t 16H25t:3: titrable N, 16.22%. Found 16.11%. 
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· 1-[,8-<Methyl-1,2, 3 ,4-tetrahydro-o<..-naphthylami no )ethyl]-4-
methylpi perazi ne 
A mixture of 25.9 g. (0.1 mole) of 1-[,8-( 1,2,3,4-tetrahydro-
o(-naphthylamino)ethyl]piperazine, 19.5 g. of formaldehyde (37%) 
and 12.0 g. of formic acfd (98+ %) was placed in a round bottom 
flask and heated on a steam bath for three hours. The mixture 
was then refluxed overnight. Concentrated hydrochloric acfd (13~g.) 
was added and the excess formaldehyde and formic acid were removed, 
by distillation at reduced pressure. The residue was dissolved in 
water and made alkaline by the addition1of 40% NaOH. The oil 
which separated was extracted with thr:ee 50 ml. portions of ether. 
The ether extracts were combined and the ether evaporated. The 
liquid residue was distilled. 
Yield: 19.9 g. (69.3%), b.p. 166-170°@ .6mm. 
Calculated for c18H N : titrable N, 14.62%. Found 14.36%. 29 3 
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t-[p-(Dfcyc1 opropy1methylamf no)ethyl]pf peraztne 
To 12.4 g. (0.1) mole) of dicyclopropyl ketone dissolved in 
7S ml. of toluene was added 14.6 g. (0.11 mole) of ;ta-amfnoethyl~ 
piperazine wfth shaking.· An addftfona1 SO· mt. of toluene was added 
and the mixture was allowed to reflux with a water trap attached. 
Approximately 2 ml. of water was collected overnight. Host of the 
toluene was distf lted off under reduced pressure and to the resulting 
residue was added a large excess of NaBH4 (approximately 7 g.) 
dissolved in 100 mt. of methanol. The reduction took place fn about 
four hours. The resulting solutf on was made more baste by the 
addition of 15 g. of NaOH dissolved in 50 ml. of H2o. After cooling, 
the soJutf on was extracted three times with 50 ml. portions of 
ether. The ether layers were combined. The remaining water-methanol 
layer was concentrated by evaporation and extracted with 50 mt. 
of ether. This ether extract was combined with the three previous 
ether extracts and the ether evaporated. The resulting lfqufd 
was dfstf Hed. 
Yfe1dt 3.0 g. (12.2%). b.p. 163-168° @ Snm. 
Calculated for C H N : titrable N, 18.81%. Found 18.76%. 
13 2S 3 
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1-[,s -(::i<-Cyclopropy1ethylamino)ethy1] pfperazfne 
C> -CH-NH-CH -CH -0 , 2 2 
CH3 
To 64.S g. (O.S mole) of ..B-amfnoethylpf perazf ne dfssolved f n 
SO ml of methanol was added 34 g. (0.4 mole) of meth~ cyc1opropyl 
ketone wf th shaking. The mixture was then allowed to reflux for one . 
week. The mixture was treated with lS g. of NaBH4 in SO m1. of methanol. 
The methanol !·:as evaporated. The resulting viscous gum was dissolved 
slowly with mechanical stirring and cooling fn 300 ml. of 6,?! HC1. 
The resulting acid solution was extracted three times with 50 ml. 
portions of ether. The ether extracts were discarded. The acid 
layer was then made basic with excess solid NaOH. During thfs process 
the mixture was cooled fn fee. An of 1 rose to the surface. This 
mixture was then "'-:"'tr acted three times wf th 100 ml. portf ons of 
ether. The ether extracts were conbfned and the ether evaporated. 
The resulting lfqufd was dfstflled. 
Yield: 25.S g. (32.3%), b.p. 0 153-158 @> 19.2nm. 
40 
To )0 .. 4 g. (0.2 mole) of citral dissolved in 100 ml. of 
toluene was added 25.8 g. (0.2 mole) of /3 -aminoethylpiperazine 
with swirling. Heat was evolved. The mixture was refluxed usfng a 
water trap. A quantitatfve yield of water was obtained f n about 
2 hours. To the mixture was added 6 g. of NaBH4• Ho reaction was 
observed unti 1 a sample of methanol was added. Complete solution 
took place after 50 ml. of methanol had been added f n smal 1 portions. 
The mixture was left standing overnight and a solid separated out 
of solutfoni The methanol and toluene were evaporated. The viscous 
gun whfch resulted was dissolved., with cooling. in 120 ml. of 
6!! HCJ. This acid solution was extracted with two 100 mt. portions 
of ether. The ether extracts were discarded. To the acid layer 
was added excess solid RaOff wfth cooling and an oil rose to the 
surface. This basic solution was extracted with two 100 ml. portions 
and three 50 ml. portions of ether. TI1e ether extracts were combined 
and the ether evaporated. The resulting viscous liquid was dlsti11ed. 
Ytel~s t0.9 9- (20 • .5%)~ b.p. 168-172°@ .tam. 
Calculated for c16tt31 N31 tftrabte ff# 15.83%. Found JS.36%. 
41 
l·[J3.-(2-Isopropy1-5-methy1cyc1ohexy1amino)ethyj] pfperazine 
H~:H-Clti-CH2-~ 
1 
CH3 
To 15.4 g. (0.1 mole) of menthone di~solved in SO ml~ of abs-
olute methanol was added t2.9 g. (0.1 mole) of fi-aminoethy1piperazine 
with shaking. The mixture was allowed to stand overnight. To the 
mixture was added 3 g. of NaBH4• TI-ie mixture was allowed to stand 
until the evolution of hydrogen ceased. which required about li hours. 
The methanol was evaporated and to the resulting viscous liquid was 
added 100 ml. of water. The liquid did not dissolve completely in 
the water. This mixture ~tas then extracted with 100 ml. of ether. 
To the water layer was added 20 g. of solid NaOH. After cooling. this 
basic layer was extracted with a mixture of 100 ml. of ether and 2S ml. 
of butanot. The ethor-butonol layer was removed and to the baste layer 
was added an additional 20 g. of solid NaOtt" After cooling~ this 
basic layer was extracted with 100 ml. of ether. Then«> ether extracts 
and the ether-butano1 extract were combined and the volatile material 
was evaporated. The residue was distilled. 
Yield: 4.s4 g. (17.0%), b.p. 160-161+0 @ .o2mn. 
Calculated ~or C16H33N3: titrab1e N, 15.71%. Found IS.23%. 
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1- !e-[)-(2.6,6-Trimethy1-2-cyclohexeny1)-1-methy1-2-propenylami~ 
ethyl} pfperazfne 
To 19.2 g. (ti.1 cute) of o<.-ionone dissolved in SO ml. of abs-
olute methanol was added 12.9 g. (0.1 mole) of ,6'-amfnoethy1pfperazfne 
with shaking. The mixture was allowed to s~and for about 3 hours 
and then 3 g. of NaBH4 was added. The mixture was a11owcd to stand 
~ 
\tnti1 the evolution of hydrogen ceased. The methanol was evaporated 
and 100 ml. of water was added to the residue. The residue was not 
completely soluble fn the water. 'Tilf s mixture was extracted wfth two 
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100 ml. portions ant'! one 50 ml. portfon of ether. To the water layer was 
added 20 g. of solfd MaOff. The resulting mixture was coo,1ed and ex-
tracted with 75 ml. of ether. The ether extracts were combined and 
the ether evaporated. TI1e liquid residue was distilled. 
Yfeldt 7.3 g. (23.9%), b.p. t80-t85° (/fl .OSmm. 
Calculated for C19H3sff3t titrabte N, IS.71%. Found IS.23%. 
t- [i-(2-Hydroxy-1,2-dfphenylethytamino)ethyf] pfperazine 
To 21.2 g. (0.1 mole) of benzoin dis~olved fn 100 ml. of 
hot toluene was added 12.9 g~ Co.1 mole} of P -aminoethylpiperaztne 
with shaking. The mixture was refluxed wf th a water trap attached. 
A quantitatfve yfeld of water was obtained withtn ten minutes. 
ihe ref luxf ng was stopped and three 3 g. of NaBH4 was added. Then 
70 ml. of methanol was added. The addition of the methanol took 
the NaBH4 into solution resulting in the evolution of hydrogeo. 
following reduction, about ti hours, the,methano1 and toluene we~e 
evaporated and the resulting.viscous gU'lf. was dissolved in 70 mJ. 
or 6N HCl with cooling fn ice. The acid solution was extracted 
-
with 100 ml. and two SOml. portions of ether. The acid layer 
was then made basic with excess solid NaOH while cooling. A 
viscous gum then rose tc. the surface. The basic solution and gum 
were extracted with one 100 ml. and two 50 ml. portions of ether. 
The ether was evaporated and the residue distilled. 
Yield; 13.0 g. (40.0%); b.p. 233-237° @ .1Sr.m. 
Calculated for c20tt27N3o: , titrabte,:ff, 12.91%. Found t2.39X. 
1- [B-(3Tropy1amino)ethyl]pfperazine 
To 10 g. (0.07 mole) of tropfnone dlissolved in apporxiimately 
75 ml. of absolute methanol.was added 9 g. (0.07 mole) of /3 -amino-
ethylpfperazine. The mixture was allow to stand overnight. To 
the mixture was added 2.8 g. of NaBH4 and when the evolution of 
hydrogen ceased the methanol was evaporated. The resulting viscous 
gun was di sso 1 ved in water and so 1i d NaOH was added untf t two 
distinct layers wre formed. An attempt was made to extract the 
mixture with ether but the upper organic layer did not dissolve 
to any appreciable extent in the ether. thus forming three layers. 
The upper and middle layers were separated from the lower layer. 
The lower layer was extracted with approximately 75m1. of ether. This 
ether layer was added to the upper and·mfddle layers. The lower 
layer was treated\.with solid NaOll and the upper )ayer thus formed was 
added to the ether layers already obtained. The ether was evaporated 
and the resulting viscous liquid was cfsti11ed. 
Yields ;.8 g. (21 .5%}, b.p. 1160-164°" @ .1nm. 
Calculated for c14H28M4: titrabte N, 22.20%. Found 22.0)%. 
45 
t{P-~-Cyctopropylbenzylamfno)ethy[]pfperazfne 
To 64.S g. (0.5 mole) of p -aminoethyl pf perazfne dissolved in 
SO ml. of methanol was added 73 g. (O.S mole) of pheny1cyc1opropyf 
ketone wtth shaking. The mixture was allowed to reflux for one 
week. Part of the methanol was evaporated and 100 ml." of toluene 
was added and the toluene dfstf Jled. Durfng thfs dfstf11atfon 
about S ml. of tt2o· was removed from the dfstf 11ed toluene~ To 
the resulting mixture was added IS g. of NaBH4 fn absolute methanol, 
and the methanol evaporated. The resulting vfscous gum was taken 
up wfth coolfn9 and stirring fn )00 ml·. of 6!! HC1. The acid solution 
was extracted three ti mes wf th SO ml. portions of ether •. · The ' 
ether extracts were discarded. The acfd layer was then made basic 
with excess solid NaOH and extracted three times with 100 ml. 
portf ons of ether •. The ether extracts were cord>fned and the ether 
evaporated. The resultfng lfqufd was dfstf Jted. 
Yield: 1s.3s g. (15.8%), b.p. 118-182° @ .5mn. 
. . . 
Ca1cu1ated for c14H23n3: titrable N, 16.20%. Found 16.37%. 
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1-C,B-(8-Pyridylmethyl amino)ethyLJpf perazine 
To a solution of 38.7 g. (O.JO mole) of fo -aminoethylpfperazfne 
dissolved in 25 ml. of absolute methanol was added 32.1 g. (0.30 mole) 
of 3-pyrfdinecarboxa1dehyde with shaking. The mixture was allowed 
to stand for 15 minutes. after which 7.6 g. (0.2 mole) of NaBH4 
in 100 ml. of methanol was added with shaking. Upon completion of 
reduction the methanol was evaporated using an evaporator. Two 
1 ayers appeared. To this mixture was added 200 ml • of 6!! NaOH 
and the baste mixture was extracted with 250 ml. of ether. To 
the ether layer was added 100 ml. of 12!! HCt and the mixture was 
cooled in an ice bath. An additional 200 ml. of ether was added 
and the entire upper layer was separated and discarded. To the lower 
acid SC>Jution was added 6!! NaOH unti I it became strongly baste. All 
the product remained in solution. The solution was saturated with 
soJfd K2co3• Two layers formed and the lower layer was discarded. 
The upper layer was dissolved in 300 ml. of ether and 200 ml. of 
ethanol. A White solid came out of solution and was filtered. The 
precipitate was discarded and the filtrate was dried over soJfd 
K2co3• The mixture was filtered and most of the ether evaporated. 
The remainder of the ethanol were distilled off using the water 
aspirator and the resulting viscous liquid was distilled using a 
vacullll punp. 
Yield: 32.0 g. (14.5%). b.p. 176-180°@ .)nm. 
Calculated for c12H20N41 titrable N, 25.43%. Found 25.5]%. 
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Unsuccessful attempts were made to obtain the reduced conden-
sation products of {!, -amfnoethy1piperazfne with the following ketones: 
" 
Xanthene-9..one 1,21 3,4-Tetrahydroacridone Antbr-one 
SX)-
' ) 
.... ./ I 
2-Chtorothioxanthone Ftuorenone 
These compounds were refluxed, in some cases for a week or more, 
with ~-aminoethylpiperazine f n such solvents as xylene, toluene, 
methanol and butanol, but in all case» following addition of NaBH4 
and standard purification procedures, no analyzable product was 
obtained. 
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HETiiOD OF ANALYSIS 
1be compounds prepared in this thesis were analyzed by titrating 
the bas~c nitrc:)en atoms. The compound shown, for example,, has three 
titrable nitrogen atoms. 
A small sample (0.05-Q.1S g.) of each compound was weighed, 
dissolved in g1acia1 acetic acid and titrated With standardized 
f)erchloric acid in glacial acetic ac:fd. During the titration,, the 
solution was stirred with a magnetic stirrer ~ the progress of 
the titration was followed using a Seckman Glass Electrode pH meter,, 
Model H-2. The end point of the titration was determined as the 
point of maximlln change fn potential per milliliter increment of 
tltrant added. 
The method of calculation is shown below., where 8 is the nunber 
of tf trable nitrogen atoms. 
B X Wt. of Sample X 1000 • 
ml. of ACid x N of Acid = Molecular We1ght 
B X 14.03 X 100 
Molecular Weight = %H 
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TABLE of RESULTS 
I 0 /I R-:-C~-Cffa- . -R 
-.----------~-~-........ --~~----~ .... -~--... ~ .... -..-...-~~--~~---------------.,-~ R R' R11 % Yteld B.P. Co Pressure N% 
0-
0-
-H -ff 
@-Clta- -11 
@~ 
cfr 
© 
$ 
-ti 
-tt 
-H 
-K 
-H 
-H 
-H 
-H 
an. Cale. Found 
33.5 148-150 o.6 
40.0 228-232 0.2 4.74 s.\#. 
145-150 o.s 19.17 18.98 
32.a 225-230 0.2 4.62 5.01 
18.) 143-148 0.3 15.85 15.64 
12.9 214-218 30. 1S.04 14.97 
)i\, ·. 
24.7 . 192;.196 38. 18.81 18.31 
12.0 JS0-189 16.22 16. JJ 
166-170 o.6 14.62 14.36 
12.2 163-168 s.o 18.Jl 18.76 
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TABLE of RESULTS (Cont.) 
--~-~~-~--~---~----~-...--~-~---.... -~-~------------~---~~------~-------~~~-~-R R R % Yield B.P. Co Pressure N% 
am. Cale. found 
@-Cl!- -H L -ff 178-182 }0 .. ~ 16.20 16.37 
[>-g~3 -H -H 32.3 153-158 19.2 21.28 21.03 
{CH)3C:CHCH2CH2C(CH3)=CHCJfi-
.. ff 
-H 20.s 16s-112 0.1 15.83 15.36 
-H -H 17.0 160-1611 0.02 15.71 15.23 
H3C CH3 
'" CH3 
-H 180-185 OCH=CH-CH- -ff 23.9 o.os 15.71 15.23 
CH) 
@OH ..... 
•@ t' -, 
-H 
-H 40.o 233-237 0.15 12.91 12.39 I I ,_,,, 
©C1'2-
' ... ff -H 14~5 176-180 0.3 25.43 25.57 I 
21.s 160-1611 0.1 22.20 22.os 
SUMMARY 
A series of potential pharmaceutical derivatives of p>-amino-
ethylpiperazine was prepared by condensing aldehydes and ketones 
with the primary amino group of ~-amfnoethytpiperazine to form the 
Schiff bases. The Schiff bases were reduced to secondary amines 
using sodiun borohydride. 
In nearly all of the compounds prepared, the groups attached 
to the ,P-aminoethylpiperazine nucleus are known to have medicinal 
properties which are the same as those expected of the 15'-amino-
ethylpiperazfne moiety. The compounds are expected to have one 
or more of the following activities: antispasmodic, anticholinergic, 
antihistamfnic, vasodilator, ganglionic blocking, analgesic, sympatho-
mimetfc and sympatholytic. Tite actual activities are pending the 
results of pharmacological testing by the A. H. Robins Co. Inc. 
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